Clinical Trial Update: A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study evaluating the safety, pharmacokinetics, and pharmacodynamics of PF-03635659 in patients with chronic obstructive pulmonary dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PF-03635659

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases | Phase 2 | Status: COMPLETED | Results posted: 2016-02-19